For example, in patients with lung cancer treated with anti-PD-1/PD-L1 immune checkpoint inhibitors, TMB was positively correlated with the objective response rate, progression-free survival, and clinical benefit time (Sha et al., 2020). This evidence concerns the gene CD274 and lung carcinoma.